FDA label
What is Olumiant used for?
Olumiant contains baricitinib. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Olumiant lists 3 uses: Moderately to Severely Active Rheumatoid Arthritis; Coronavirus Disease 2019 (COVID-19); Severe Alopecia Areata.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Olumiant?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Olumiant, tablet, film coated
Indications and Usage, quoted from the label by Eli Lilly and Company (NDA207924). Cross-references to other label sections are left out.
Moderately to Severely Active Rheumatoid Arthritis
OLUMIANT® is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.
Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
Coronavirus Disease 2019 (COVID-19)
OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Severe Alopecia Areata
OLUMIANT is indicated for the treatment of severe alopecia areata in adults and pediatric patients 12 years of age and older.
Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
Source: DailyMed label, set id 866e9f35-9035-4581-a4b1-75a621ab55cf, version 32, effective October 9, 2026. NDC 0002-4182, one of 3 listings for this product.
Questions
What is Olumiant used for?
The FDA label for Olumiant lists 3 uses: Moderately to Severely Active Rheumatoid Arthritis; Coronavirus Disease 2019 (COVID-19); Severe Alopecia Areata.
What drug class is Olumiant?
FDA lists baricitinib in the Janus Kinase Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.